The TDR Three Takeaways for Psilocybin Clinical Trials Psilocybin shows low risk for paranoia and thought disorders, making it a promising candidate for psychotherapy treatments.
The TDR Three Takeaways for Psychedelic Assisted Therapy Psychedelic Assisted Therapy is becoming accepted in some companies employee benefits, showing promise in treating complex mental
The TDR Three Key Takeaways about Silo SPC-14 Silo Pharma’s acquisition of SPC-14 signifies a notable advancement in Alzheimer’s disease treatment options, promising improved patient
The TDR Three Key Takeaways on Alaska and Psychedelics: Alaska’s House Bill 228 introduces a task force to explore the therapeutic use of psychedelics, marking
The TDR Three Key Takeaways for Psychedelics in the Globe and Mail: The Globe and Mail’s articles on psychedelics underline a significant shift towards their
The TDR Three Takeaways on Mushrooms in Vancouver: Vancouver councillors aim to regulate magic mushroom sales to ensure safety and community protection. Proposed regulations seek
The TDR Three Takeaways From National Geographic National Geographic, a traditionally conservative magazine, has published an informative feature on psychedelics this week. National Geographic examines
The TDR Three Takeaways for Insurance Coverage of Psychedelic Therapy: Alberta Blue Cross initiates insurance coverage for psychedelic-assisted therapy, paving the way for broader access.
The TDR Three Takeaways for Lykos: ICER’s draft report on Lykos’ MDMA-assisted psychotherapy labels clinical evidence as ‘insufficient’ for PTSD treatment. Concerns over trial design
The TDR Three Takeaways on AUD: Researchers at the University of Calgary are testing the effectiveness of psychedelic-assisted psychotherapy for treating AUD. The study aims